胃癌全胃切除术围术期口服免疫营养与标准饮食的随机对照试验
这项随机III期临床试验在胃癌全胃切除术患者中,比较标准饮食与围术期口服补充富含二十碳五烯酸(EPA)的免疫营养对体重下降的影响。结果显示,两组术后1个月和3个月体重下降百分比均无显著差异,围术期EPA免疫营养未能减少全胃切除术后的体重下降。
要点
- 围术期口服EPA免疫营养未减少胃癌全胃切除术后的体重下降
核心结论
- 基于富含EPA的口服免疫营养未能减少胃癌全胃切除术后的体重下降,与标准饮食相比无差异。
研究设计与样本
- 随机III期临床试验;127例符合条件患者中126例随机分组,124例(标准饮食61例、补充饮食63例)纳入安全性分析,123例(标准饮食60例、补充饮食63例)纳入有效性分析。
- 主要终点为术后1个月和3个月的体重下降百分比。
主要发现
- 除3例外,其余患者均行全胃切除加Roux-en-Y重建,两组基线因素均衡。
- 免疫营养组补充依从性中位数术前为100%、术后为54%。
- 手术并发症发生率标准饮食组为13%、补充饮食组为14%。
临床怎么用
- 对于胃癌全胃切除术患者,围术期口服EPA免疫营养不应以减轻术后体重下降为目的常规使用。
- 围术期营养支持决策仍需个体化评估,不能依据本试验结果推广EPA补充用于减重控制。
局限性
- 术后补充依从性中位数仅54%,可能影响干预效果评估。
- 原文未报告样本量计算、具体P值以外的统计细节及长期结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Total gastrectomy for gastric cancer is associated with excessive weight loss and decreased calorie intake. Nutritional support using eicosapentaenoic acid modulates immune function and limits catabolism in patients with advanced cancer, but its impact in the perioperative period is unclear. METHODS: This was a randomized phase III clinical trial of addition of eicosapentaenoic acid-rich nutrition to a standard diet in patients having total gastrectomy for gastric cancer. Patients were randomized to either a standard diet or standard diet with oral supplementation of an eicosapentaenoic acid (ProSure®), comprising 600 kcal with 2·2 g eicosapentaenoic acid, for 7 days before and 21 days after surgery. The primary endpoint was percentage bodyweight loss at 1 and 3 months after surgery. RESULTS: Of 127 eligible patients, 126 were randomized; 124 patients (61 standard diet, 63 supplemented diet) were analysed for safety and 123 (60 standard diet, 63 supplemented diet) for efficacy. Across both groups, all but three patients underwent total gastrectomy with Roux-en-Y reconstruction. Background factors were well balanced between the groups. Median compliance with the supplement in the immunonutrition group was 100 per cent before and 54 per cent after surgery. The surgical morbidity rate was 13 per cent in patients who received a standard diet and 14 per cent among those with a supplemented diet. Median bodyweight loss at 1 month after gastrectomy was 8·7 per cent without dietary supplementation and 8·5 per cent with eicosapentaenoic acid enrichment (P = 0·818, adjusted P = 1·000). Similarly, there was no difference between groups in percentage bodyweight loss at 3 months (P = 0·529, adjusted P = 1·000). CONCLUSION: Immunonutrition based on an eicosapentaenoic acid-enriched oral diet did not reduce bodyweight loss after total gastrectomy for gastric cancer compared with a standard diet. Registration number: UMIN000006380 ( http://www.umin.ac.jp/).
引用
- Ida S, Hiki N, Cho H, et al. Randomized clinical trial comparing standard diet with perioperative oral immunonutrition in total gastrectomy for gastric cancer. Br J Surg. 2017. PMID: 28072447. doi:10.1002/bjs.10417
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。